Laporan Laba Rugi (TTM)
Laporan Laba Rugi Coeptis Therapeutics Holdings, Inc. - Equity Warrant menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2020 12-31 |
2021 03-31 |
2021 06-30 |
2021 09-30 |
2021 12-31 |
2022 03-31 |
2022 06-30 |
2022 09-30 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | 229.16 | -16.16 | -11.65 | 0.00 | -100.00 | NaN | NaN | ∞ | 319.18 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | |||
| Cost Of Sales | 1 | 1 | 1 | 1 | 0 | 0 | ||||
| Change (%) | 0.00 | -0.19 | -0.16 | 100.00 | ||||||
| % of Revenue | 3,134.54 | 952.28 | 1,133.68 | 1,281.14 | 71.82 | 34.27 | ||||
| Gross Operating Profit | -1 | -1 | -1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change (%) | -7.55 | 1.68 | 0.96 | -108.47 | -100.00 | NaN | NaN | ∞ | 877.77 | |
| % of Revenue | -3,034.54 | -852.28 | -1,033.68 | -1,181.14 | 100.00 | 28.18 | 65.73 | |||
| SG&A | 6 | 7 | 9 | 14 | 14 | 28 | 35 | 34 | 9 | 11 |
| Change (%) | 23.79 | 27.18 | 58.57 | -2.07 | 98.97 | 25.51 | -3.60 | -74.80 | 22.85 | |
| % of Revenue | 18,777.71 | 7,061.67 | 10,712.40 | 19,225.53 | 18,827.91 | 13,623.55 | 3,992.64 | |||
| R&D | 0 | 0 | 0 | 0 | 0 | 2 | 2 | |||
| Change (%) | 0.00 | -100.00 | NaN | 7,757.22 | -6.61 | |||||
| % of Revenue | 11.52 | 3.50 | 0.00 | 0.00 | 2,610.20 | 581.52 | ||||
| OpEx | 7 | 8 | 10 | 15 | 14 | 28 | 35 | 34 | 11 | 13 |
| Change (%) | 20.37 | 23.87 | 52.95 | -8.19 | 98.97 | 25.51 | -3.54 | -66.92 | 16.83 | |
| % of Revenue | 21,923.77 | 8,017.45 | 11,846.08 | 20,506.68 | 18,827.91 | 17,896.05 | 4,987.86 | |||
| Operating Income | -7 | -8 | -10 | -15 | -14 | -28 | -35 | -34 | -11 | -13 |
| Change (%) | 19.42 | 24.38 | 53.50 | -8.23 | 100.03 | 25.51 | -3.54 | -67.11 | 15.13 | |
| % of Revenue | -21,823.77 | -7,917.45 | -11,746.08 | -20,406.68 | -18,727.91 | -17,796.05 | -4,887.86 | |||
| Interest Expense | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Change (%) | 0.16 | -0.92 | 3.19 | 23.32 | 11.27 | 9.96 | -57.71 | 175.88 | 0.65 | |
| % of Revenue | -481.75 | -146.59 | -173.24 | -202.33 | -249.51 | -424.82 | -102.00 | |||
| Net Income | -9 | -9 | -11 | -15 | -13 | -31 | -38 | -37 | -10 | -10 |
| Change (%) | 0.59 | 22.17 | 36.67 | -12.54 | 128.11 | 23.11 | -0.79 | -73.66 | 5.06 | |
| % of Revenue | -29,765.89 | -9,096.00 | -13,255.27 | -20,503.61 | -17,932.37 | -15,697.97 | -3,934.36 | |||
Source: Capital IQ
